



Long-term Functional Success and Patient-Reported Outcomes after One-Stage Buccal Mucosal Graft Urethroplasty (BMGU) for Female Urethral Stricture

(AUTHOR ET AL., 2024)

ACTAS UROLOGICAS ESPANOLAS

Background

- ▶ Female urethral stricture (FUS) causes chronic lower urinary tract symptoms.
- ▶ Traditional treatments: dilation, intermittent catheterization, or staged reconstruction.
- ▶ One-stage BMGU is increasingly used as definitive therapy.
- ▶ Limited data on long-term functional and patient-reported outcomes.

Study Objective

- ▶ Evaluate long-term functional success after one-stage BMGU.
- ▶ Assess patient-reported outcomes: satisfaction, QoL, continence.
- ▶ Identify complications and predictors of failure.

Study Design

- ▶ Retrospective multicenter cohort study.
- ▶ Inclusion: adult females with FUS undergoing one-stage BMGU.
- ▶ Follow-up: mean 5.2 years (range 2–10 years).
- ▶ Outcomes: functional success, patient-reported questionnaires, complications.

Patient Selection

- ▶ Total patients: 102 adult women.
- ▶ Mean age: 52 years (range 28–78).
- ▶ Stricture etiology: idiopathic 60%, iatrogenic 30%, traumatic 10%.
- ▶ Mean stricture length: 1.8 cm (range 0.8–3.5 cm).

Surgical Technique Overview

- ▶ One-stage BMGU performed under general/regional anesthesia.
- ▶ Buccal mucosal graft harvested and tailored to urethral defect.
- ▶ Ventral or dorsal placement based on anatomy.
- ▶ Single-stage closure with urethral stent for 2–3 weeks.

Outcome Measures

- ▶ Functional success: patent urethra, no dilation.
- ▶ Urinary flow: Qmax and PVR.
- ▶ Patient-reported: UDI-6, IIQ-7, QoL.
- ▶ Complications: incontinence, fistula, graft donor morbidity.

Follow-Up Protocol

- ▶ Clinical exam + uroflowmetry at 3,6,12 months then annually.
- ▶ Flexible cystoscopy if recurrence suspected.
- ▶ Patient-reported outcomes collected at 12 months and last follow-up.
- ▶ Mean follow-up: 62 months.

Functional Outcomes: Success Rate

- ▶ Overall functional success: 91% (93/102).
- ▶ Mean Qmax increased 7.2 → 18.5 mL/s.
- ▶ Mean PVR decreased 110 → 18 mL.
- ▶ 9 patients required secondary intervention.

Long-Term Patency

- ▶ Patency rates stable: 95% at 2 yrs, 91% at 5 yrs.
- ▶ Recurrences mostly within first 12 months.
- ▶ No significant difference based on graft placement.

Patient-Reported Outcomes

- ▶ 88% reported improved urinary symptoms and QoL.
- ▶ UDI-6 and IIQ-7 improved 65–70% from baseline.
- ▶ Minimal post-op urinary incontinence (<5%).
- ▶ High patient satisfaction.

Continence and Sexual Function

- ▶ Stress incontinence: 3% de novo, 2% pre-existing persisted.
- ▶ Sexual function not significantly affected.
- ▶ No urethrovaginal fistula reported.

Donor Site Morbidity

- ▶ Buccal harvest complications minimal: transient pain 15%, numbness 10%.
- ▶ No long-term oral dysfunction.
- ▶ Patients resumed normal diet within 3 days.

Complications

- ▶ Early post-op: UTI 8%, mild hematuria 5%.
- ▶ Late: recurrence 9%, managed with dilation or redo BMGU.
- ▶ No graft loss or severe complications.

Predictors of Failure

- ▶ Short stricture length (<1 cm) not predictive.
- ▶ Multiple prior urethral surgeries slightly higher recurrence.
- ▶ Ventral vs dorsal placement not predictive.

Comparative Outcomes

- ▶ Compared to staged repairs: similar long-term patency.
- ▶ One-stage BMGU: faster recovery, fewer hospital visits.
- ▶ Cost-effective and high patient satisfaction.

Clinical Implications

- ▶ One-stage BMGU is safe and durable for FUS.
- ▶ High functional success with sustained patency.
- ▶ Excellent patient-reported outcomes support QoL benefits.

Limitations

- ▶ Retrospective design, potential selection bias.
- ▶ No randomized control group.
- ▶ Some patient-reported outcomes missing.
- ▶ Results mainly from high-volume centers.

Recommendations

- ▶ One-stage BMGU should be first-line in suitable patients.
- ▶ Patient counseling: excellent long-term outcomes.
- ▶ Encourage standardized reporting for multi-center comparisons.

Conclusion

- ▶ One-stage BMGU yields >90% long-term functional success.
- ▶ Sustained improvements in urinary flow and patient satisfaction.
- ▶ Low complications, minimal donor-site morbidity.
- ▶ Versatile, safe, patient-centered approach.